GRAIL's BofA Presentation Reaffirms MCED Focus, No New Catalysts

What happened

GRAIL presented at the Bank of America Global Healthcare Conference, emphasizing its focus on the Galleri test and progress toward PMA submission. Volumes continue to grow, but average selling prices remain under pressure from mixed payer dynamics. Management reiterated a disciplined approach to cash burn, targeting ~$325 million for 2025, though operating losses remain substantial at $(125) million in Q3. The regulatory landscape for LDTs remains unsettled after the April 2025 court decision, adding uncertainty to commercialization. No material new data or guidance was provided, leaving the investment thesis unchanged and dependent on binary regulatory and reimbursement outcomes.

Implication

Long-term value hinges on successful PMA approval and broad reimbursement; investors should monitor PATHFINDER-2 data and the 100k Medicare study, which could unlock adoption but remain elusive until 2026 or later.

Thesis delta

No shift from the existing HOLD thesis. The BofA presentation reaffirmed ongoing execution without altering the balanced risk/reward profile, as neither regulatory nor reimbursement catalysts have been resolved.